Group 1 PRPM128 Linga, Xyza Vera BSP3F Manzano, George Salazar, Jermaine Ghel Sanchez, Maria Vivien Vera Tampilic, Maria Angelica Yanesa, Jediael Zabella, Chaira Mae Genato, Charles Sanchez, Ray M2 Check-in Activity: Fact-Finding Activity Viruses Similarities and Differences Clinical Features Coronaviruses and Influenza Epidemiologic Variables SARS-CoV MERS-CoV coviD-19 Genus Betacoronavirus | Betacoronavirus | Betacoronavirus | Influenza Virus A Natural Civet Cats: Dromedary Bats Birds Source/Reservoir CamelsMajor Signs and Fever, chills, dry] Fever, cough, Fever or chills, Fever or chills, Symptoms | cough, muscle | shortness of | cough, difficulty | cough, sore aches, breath breathing, throat, runny headache, fatigue, nose, diarthea, musclefbody | muscle/body shortness of aches, aches, breath headache, loss | headaches, of taste or smell, | fatigue, voriting sore throat, | and diarthea, congestion or runny nose, nausea or vomiting, diarrhea Mode of Contact routes, | Animal-to-huma | Respiratory Droplets, Transmission droplet, 1 transmission droplets, contact routes alrbome, unprotected | contact routes contact withfomite, fecal-oral bloodborne, mother-to-child, and animal-to-huma 1 transmission. infected dromedary camels or infected people. Person-to-Person Transmission Yes Incubation Period | 2-7 days 6 days 4-14 days 1-4 days Treatment | There isno cure | There is no Antiviral Antiviral drugs or vaccine for | specific antiviral | treatments | Supportive care SARS and treatment Monocional treatment recommended antibodies. shouldbe | for MERS-CoV supportive and infection, based on the | Individuals with patient's MERS often symptoms. | receive medical care to help relieve symptoms, Susceptible 60 years or older with health conditions like lung or heart disease, Population diabetes, and people who have weakened immune systems.Diagnosis Nucleic Acid Real-time Reverse- viral culture, Amplification reverse- transcription | serology, rapid Tests (NAATs, | transcription polymerase | antigen testing, such as polymerase | chain reaction reverse Reverse chain reaction (RT-PCR), transcription Transcription— | (RT-PCR) antigen tests polymerase Polymerase chain reaction Chain Reaction) (RT-PCR), and antigen immunofluoresc tests ence assays, and rapid molecular assays. Xray Pattem | Ground-glass | Ground-glass | Ground-glass | Small patch; opacities Lung | opacities; | opacities: single | Ground glass consolidation: Lung or multiple focal; | opacities (GGO) focal, multifocal, | consolidation; Lung and or diffuse Lung consolidation; | consolidation (primarily involvement: Patchy with subpleural peripheral) | bilateral (80%) | consolidative and/or peri- Lung or unilateral opacities; bronchial involvement: | (20%); Pleural | Pulmonary distribution unilateral effusion; nodules; (two-thirds of | Intralobular Interlobular patients) or | septal thickening septal bilateral thickenina: Annual Cases | 8,098 cases in | 739 (2014) 82,000,000 | 9,000,000 cases 23 countries 768 (2015) cases since as lowest to during the 2003 | 244 (2016) | December 13, | 30,000,000 outbreak 244 (2017) | 2019 to January | cases as highest 113 (September | 02, 2021 per year from 2018) 2010-2017 Hospitalization | Most cases Most cases ~19% 2% Rate Case Fatality 96-11% 34.4% 3.4% 0.05-0.1% Rate— CFRReferences Middle East respiratory syndrome coronavirus (MERS-CoV) (who int) https:/www.ede.govifiu/about/keyfacts. htm https:/wwnw.ede.gov/sars/surveillance/absence.html https://ejmm.springeropen.com/articles/10.1186/s43055-020-00296-x hitps:/www.ede.govifiu/about/keyfacts.htm#:~:text=Median%20incidence% 20values%2 https:/www.cde.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.htm! https:/www.cde.gov/coronavirus/mers‘aboutisymptoms. html https:/www.mayaclinic.orgidiseases-conditions/sars/symptoms-causes/sye-20351765 https:/www.cde. govifiu/symptoms/symptoms.htm https:/www. who iint¢news-room/¢ommentaries/detalltransmission-of-sars-cov-2-implications-for-| nfection-prevention-precautions https:/www.who int¢news-room/fact-sheets/detall middle-east-respiratory-syndrome-coronavirus-( mers-cov) hitps://relietweb intreportworld/modes-transmission-virus-causing-covid-19-implications-ipe-prec aution-recommendations ?gclid=CjOKCQjw-daUBhClARIsALbkjSZ4Z3| pbBr6C3_GZBPuNFOTX2 32JvA27KUiol7EsxXmFnyNymrR73QaArOuEALW_wcB https:/www.cde.govifiu/aboutidisease/spread. him#:~-text=F e220,be%20inhaled%20into%20the%20|ungs. https:/www.cde.gov/coronavirus/2019-ncavihcpltesting-overview.himit:~text=Test%20Types info 1m%20an%20individual's%20medical%20care, https:/www.cde.gov/coronavirus/mers/labllab-testing htm! https:/www.cde.gov/coronavirus/2019-ncov/hepltesting-overview.htmi#:~:text=Test%20Types info rm%20an%2Oindividua's%20medical%20care. https:/wwnw.ede.govifiu/professionals/diagnosis/labrolesprocedures.htm#:~:text=Diagnostic'%20te sts%20available%20for%20influenza, assays%2C%20and%20rapid %2Omolecular%20assays hitps:/www.researchgate.net/profile/Jacek-Bajipublication/242030425/figureltbl1/AS:9004381865 28774@1591692601989/Clinical-features-of-severe-acute-respiratory-syndrome-coronavirus-SA RS-CoV-Middle png eople%20with%20Mlu%20can%20spr https Aww. who ini/health-topies/severe-acute-respiratory-syndrome#tab=tab_3 httpsiwwrw.cd. govicoronavirus/mers/about/prevention.html https JAwrw.cde.govifultreatmentiindex. html https Aww. ede. govicoranavirus/20 19-ncovlyour-health/reatments-for-severe-ilness.html https:Jiwww.cde.govidotwisarstindex him https:JAww.cde.govisarstaboutfs-SARS. pdt https:sAwwrwnc. cde. govisid/artcle/25/9/19-0143_article httpsJAvorldmapper.orgimaps/coronavirus-cases! https:JAww.unicet.orgimedia/9615 1 file/Corrigendum-UNICEF-Final-2020-Global-Covid-19-Situat ion-Report-Fab-Dec-2020. pdf https Awrw.cde.goviflulaboutfburden/past-seasons.htmn! https shwww. news 10,comvnews/coronavirus/comparing-coronavirus-to-the-flu-and-other-respirator ysilnesses! https:uAww.news10.com/news/coronavirus/comparing-coronavirus-to-the-flu-and-other-respirator y-ilnesses! https Aww. news10.cominews/coronavirus/comparing-coronavirus-to-the-lu-and-other-respirator ysilinesses! bclid=IwAR3vWwhx0rXeydKb4aqJOL2PUOTARMhSF.JOQ_gwéxgnt Ydk/4uPio 1 QUXt Fw